Orphan Drug Advantage Alkermes has earned orphan drug designations in the US and Europe for alixorexton, including for idiopathic hypersomnia and narcolepsy. This creates regulatory incentives and potential market exclusivity, improving attractiveness for regional partnerships, licensing deals, or co development with specialty distributors.

Sleep Disorder Focus The alixorexton program targets narcolepsy and idiopathic hypersomnia with Phase 3 under way, signaling a large addressable sleep disorder market and opportunities for co commercialization, regional licensing, or strategic collaborations to accelerate market access.

Global Ops Capabilities A distributed footprint with headquarters in Ireland, a US R&D hub in Massachusetts, and a manufacturing facility in Ohio provides near term scalability for joint manufacturing, supply, and distribution collaborations across US and international markets.

Patient Centric Brand Alkermes has patient inspired science and has been recognized as a Best Workplace, signaling collaboration value and readiness to support patient access programs, payer strategies, and adherence focused initiatives with partners.

Pipeline Catalysts Positive Phase 2 data for Vibrance 2 in narcolepsy type 2 and ongoing orexin 2 program milestones offer near term engagement points for co development or licensing discussions and expansion into additional sleep and neuropsychiatric indications.